MediWound Ltd - יחס שווי פעילות לרווח לפני ריבית, מסים ופחת MDWD

MediWound Ltd. is developing its burn therapy segment through partnerships with hospitals and biotech holdings. This chart's price action reflects an EV/EBITDA multiple of 0.00. The business relies on the expansion of NexoBrid, which is in high demand within emergency and military medicine. However, the company faces pressure from global behemoths capable of scaling the production of similar enzyme-based drugs more rapidly.

Rising demand for MediWound Ltd. (MDWD) enzymatic preparations is expanding its hospital distribution network. The EV/EBITDA metric, including depreciation and debt, correlates the total enterprise value with operating profit before taxes, depreciation, and amortization. This chart's price action allows market value to be stripped of accounting distortions and the impact of debt load. The stability of this multiple confirms the company's fundamental resilience amid the expansion of medical standards.